Supplementary Figure 1. A B B12 (nM) 500 500 500 500 0.15 0.15 0.15 0.15 - - - Folate (µM) 6 15 30...
5
upplementary Figure 1. A B B12 (nM) 500 500 500 500 0.15 0.15 0.15 0.15 - - - Folate (µM) 6 15 30 60 6 15 30 60 - 30 60 Control Series1 50 100 150 Total Cholesterol (%) * * ** * * ** ** Series1 0 1 2 3 Homocysteine (uM) * ** ** ** * * ** B12 (nM) 500 500 500 500 0.15 0.15 0.15 0.15 - - - Folate (µM) 6 15 30 60 6 15 30 60 - 30 60 Control *
-
Upload
isaac-brown -
Category
Documents
-
view
217 -
download
0
Transcript of Supplementary Figure 1. A B B12 (nM) 500 500 500 500 0.15 0.15 0.15 0.15 - - - Folate (µM) 6 15 30...
Supplementary Figure 1.
A
B
B12 (nM) 500 500 500 500 0.15 0.15 0.15 0.15 - - -
Folate (µM) 6 15 30 60 6 15 30 60 - 30 60
Control
Se-ries1
50
100
150
To
tal
Ch
ole
ster
ol
(%)
**
***
*
****
Se-ries1
0
1
2
3
Ho
mo
cyst
ein
e (u
M)
*
**
**
**
**
**
B12 (nM) 500 500 500 500 0.15 0.15 0.15 0.15 - - -
Folate (µM) 6 15 30 60 6 15 30 60 - 30 60
Control
*
Supplementary Figure 2: Bisulphite-Pyrosequencing Amplicon
B LDLR
A SREBF1
TGATTTTGCTTTGAGGGAGAGGAAACCG1CCCTTCTGTTTGTTCAACTCCTTCTCCTAAGGGGAGAAATCAATATT
TACG2TCCAGACTCCAGGTATCCG3TACAATTGATTTTTCAGATGTTTATACTCAGCCAAAGGCG4GGATCCCACAA
AACAAAAAATATTTTTTTGGCTGTACTTTTGTGAAGATTTTAT
CCCTGCCTGGGCTCTGATGCAAATGCACTGGCTTCAAGCCAGGCCTCCAGTGCG4AGGTTGCG3CCTA
CCCCG2GCAACAAGCACACCAGGACTGCTAGTAACAGGGCATCTCAAGCAGCCG1AGTGGAGCCCCAG
TTTCTAAAGCCTGCACAGACCTCT
Flanking primer sequences for BS-Pyrosequencing amplicon
CpG sites
Sequencing Primer
Location of Illumina 450k probe (cg27407935) and bisulphite
pyrosequencing assay
Location of Illumina 450k probe (cg22971501) and
bisulphite pyrosequencing assay
A
SREBF1
BLDLR
Supplementary Figure 3
A
B
Supplementary Figure 4
PPARγ binding site
TSS
C/EBPα binding site
LDLR
PPARγ binding sites
TSS TSS
C/EBPα binding sites
SREBF1 TSSTSS
TSS TSS
Supplementary Figure 5: Effect of B12 in primary human adipocytes
Control LB NoB50
75
100
125
150
175
To
tal
cho
lest
ero
l (%
)
**
******
Control LB NoB0
1
2
3
Ho
mo
cyst
ein
e (u
M)
****
Control LB NoB0
1
2
3
4
SREBF1
Rel
ativ
e m
RN
A e
xpre
ssio
n
*****
Control LB NoB0
1
2
3
4
SREBF2
Rel
ativ
e m
RN
A e
xpre
ssio
n
******
Control LB NoB0
1
2
3
4
LDLRR
elat
ive
mR
NA
exp
ress
ion
*****
A B C
D E
